Natco Pharma Ltd (NATCOPHARM)
₹834.75
Mkt cap
₹14,842 Cr
P/E ratio
13.00
P/B
1.62
Div yield
0.60%
ROE
16.90%
ROCE
17.10%
EPS (TTM)
₹64.21
Book value
₹515
52W range
793–1,206
Sector
Healthcare
Price history
Previous close
NATCO Pharma Limited (NATCO) is a vertically integrated, research and development focused pharmaceutical company engaged in developing, manufacturing, and marketing complex products for niche therapeutic areas. [1] NATCO has established its presence in all three business segments viz. finished dosage formulations (“FDF”), active pharmaceutical ingredients (“APIs”), Contract Manufacturing Business. [2]
NSE NATCOPHARMBSE 524816
Health check
Constructive
ValuationCheap
ProfitabilityStrong
GrowthModerate
TechnicalsBearish
52-week range
−30.78% from high₹835
₹793+5.27% from low₹1,206
Current
₹834.75
Prev close
₹827.70
Day
+0.85%
Price performance
1D
+0.85%
1W
−0.80%
1M
−8.93%
3M
−3.50%
6M
−12.42%
1Y
−3.47%
YTD
−6.53%
Financials
Revenue, profit & margin
P/E ratio
13.0×
NATCOPHARM is 62% below the sector median of 34.0×
NATCOPHARM13.0×
Sector median34.0×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,140 | 1,031 | 759 | 1,068 | 1,363 | 1,371 | 475 | 1,221 | 1,329 | 1,363 | 647 | 739 | 735 | |
| Expenses | 612 | 573 | 490 | 571 | 558 | 567 | 436 | 673 | 758 | 784 | 489 | 612 | 549 | |
| Operating Profit | 528 | 458 | 268 | 497 | 805 | 804 | 39 | 548 | 571 | 579 | 159 | 128 | 186 | |
| OPM % | 46% | 44% | 35% | 47% | 59% | 59% | 8% | 45% | 43% | 42% | 25% | 17% | 25% | |
| Other Income | 20 | 29 | 37 | 42 | 48 | 64 | 176 | 66 | 62 | 100 | 58 | 78 | 59 | |
| Interest | 4 | 4 | 5 | 6 | 5 | 4 | 4 | 10 | 3 | 13 | 10 | 11 | 13 | |
| Depreciation | 44 | 44 | 44 | 56 | 44 | 46 | 47 | 98 | 58 | 52 | 46 | 50 | 47 | |
| Profit before tax | 500 | 440 | 256 | 478 | 804 | 818 | 164 | 506 | 572 | 614 | 161 | 144 | 186 | |
| Tax % | 16% | 16% | 17% | 19% | 17% | 17% | 19% | 20% | 16% | 16% | 13% | -62% | 34% | |
| Net Profit | 420 | 369 | 213 | 386 | 668 | 676 | 132 | 406 | 480 | 518 | 151 | 269 | 206 | |
| EPS in Rs | 23.47 | 20.60 | 11.88 | 21.57 | 37.32 | 37.81 | 7.43 | 22.70 | 26.84 | 28.94 | 8.46 | 14.96 | 11.53 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −1.14% · closed higher next day 29 of last 60
| Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 14 Nov '23◦ | 14 Feb '24◦ | 27 May '24◦ | 12 Aug '24◦ | 12 Nov '24◦ | 12 Feb '25◦ | 28 May '25◦ | 12 Aug '25 | 14 Nov '25◦ | 12 Feb '26 | 29 May '26 | 14 Aug '26 |
| Earnings day | −4.48% | +0.26% | +0.28% | −1.30% | −1.72% | −20.00% | +3.64% | −1.28% | +1.02% | −1.29% | −13.60% | −5.10% |
| +1 day | −2.63% | +16.01% | +1.15% | −2.38% | −1.03% | −27.54% | +2.45% | +0.49% | +0.23% | −3.17% | −20.62% | −6.50% |
| +5 days | +0.67% | +14.03% | −5.74% | −1.51% | −2.39% | −34.92% | −0.06% | −1.22% | +3.52% | +4.41% | −24.02% | −7.28% |
| +15 days | −1.48% | +14.76% | +13.90% | +4.15% | +4.25% | −32.31% | +2.24% | −4.92% | +10.47% | +19.85% | −24.39% | −13.03% |
| +30 days | +2.15% | +12.94% | +15.02% | −5.23% | +0.47% | −33.96% | +15.77% | −6.39% | +10.41% | +14.50% | −16.66% | — |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Jun 202649.41%Promoter
Promoters49.41%
FIIs16.99%0.38
DIIs5.63%0.17
Public27.97%0.23
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹1,899.00 | 36.07 | 4,55,634 | 0.84% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| DIVISLAB | ₹9,100.00 | 81.09 | 2,41,576 | 0.33% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| TORNTPHARM | ₹4,857.00 | 82.80 | 1,84,745 | 0.78% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| CIPLA | ₹1,385.00 | 31.26 | 1,11,888 | 0.94% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| ZYDUSLIFE | ₹1,120.00 | 22.95 | 1,11,720 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| LAURUSLABS | ₹1,840.00 | 90.93 | 99,417 | 0.11% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| LUPIN | ₹2,110.00 | 16.20 | 96,483 | 0.85% | 1,417 | +16.08% | 8,277 | +32.04% | 29.93% |
| NATCOPHARM | ₹828.65 | 12.97 | 14,842 | 0.60% | 207 | −57.04% | 735 | −44.68% | 17.14% |
| Median: 158 Co. | ₹421.50 | 33.96 | 2,277 | 0.08% | 13 | +30.25% | 164 | +18.67% | 14.96% |
Filings
Annual reports15
Annual Report 2026bseAnnual Report 2025bseAnnual Report 2024bseAnnual Report 2023bseAnnual Report 2022bseAnnual Report 2021bseAnnual Report 2020bseAnnual Report 2019bseAnnual Report 2018bseAnnual Report 2017bseAnnual Report 2016bseAnnual Report 2015bseAnnual Report 2014bseAnnual Report 2013bseAnnual Report 2013nse
Concall transcripts100
TranscriptAug 2026PPTAug 2026RECAug 2026PPTAug 2026TranscriptJun 2026PPTJun 2026RECJun 2026TranscriptFeb 2026RECFeb 2026PPTFeb 2026RECFeb 2026TranscriptNov 2025PPTNov 2025RECNov 2025TranscriptAug 2025PPTAug 2025RECAug 2025TranscriptJul 2025PPTJul 2025TranscriptJun 2025PPTJun 2025RECJun 2025TranscriptFeb 2025PPTFeb 2025
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Newspaper Publication 5 SepNotice Of 43Rd Annual General Meeting 4 SepBusiness Responsibility and Sustainability Reporting (BRSR) 4 Sep - Natco Pharma's Annual Report 2025-26 details ESG policies, goals, operations, workforce data, and sustainability performance.Reg. 34 (1) Annual Report. 4 SepBoard Meeting Intimation for Fund Raising 4 Sep - Board meeting on September 9, 2026 to consider raising funds through equity or other securities.